AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7954417
Drug: Vorozole 1
RxNorm normalized name: vorozole
DrugBank: Vorozole (DB13767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole 1 mg
Trial: 7954417
Drug: Vorozole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole 2.5 mg
Trial: 7954417
Drug: Vorozole 5
RxNorm normalized name: vorozole
DrugBank: Vorozole (DB13767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole 5 mg
Trial: 7954417
Drug: Vorozole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole (all doses)
Trial: 3300966
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjuvant endocrine therapy)
Trial: 20929123
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine for nourishing yin and clearing heat therapy (CM therapy)
Trial: 20929123
Drug: Standard Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Western medical therapy
Trial: 6341904
Drug: Sulphamethizole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphamethizole (1 g eight-hourly)
Trial: 30605952
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBT-i)
Trial: 30605952
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT-i with tapered hypnotic agents
Trial: 17638699
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg bevirimat
Trial: 15868998
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 2 ml just before induction)
Trial: 8531545
Drug: Pyronaridine 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyronaridine 32 mg/kg, orally divided over 3 days
Trial: 8531545
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg/kg, orally divided over 3 days
Trial: 26798083
Drug: Injections in
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections in the abdomen
Trial: 1857645
Drug: Injections in
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections in the thigh
Trial: 1857645
Drug: Injections in
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections in the arm
Trial: 6418506
Drug: hypertonic salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic salt and mannitol solution (415 mosmol/l)
Trial: 6418506
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isotonic saline mannitol solution with 105 mmol/l sodium, 93 mmol/l chloride, 10 mmol/l potassium and 22 mmol/l bicarbonate as well as 70 mmol/l mannitol (or 70 mmol/l polyethylene glycol)
Trial: 23063624
Drug: Home-based functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based functional exercises (twice-weekly 60-minute sessions for 6 months)
Trial: 12562649
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) and adjuvant chemotherapy (ACT) every 2 weeks with granulocyte-macrophage colony-stimulating factor (GM-CSF) support (arm B, 'dose-dense treatment')
Trial: 12562649
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) and adjuvant chemotherapy (ACT) every 3 weeks (arm A, 'standard treatment')
Trial: 12562649
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms received three courses of CEF followed by local therapy and three courses of CEF alternated with three courses of CMF.
Trial: 12562649
Drug: Dose intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose intensity of chemotherapy in arm B
Trial: 12562649
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of treatment in arm B
Trial: 12562649
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of treatment in arm A
Trial: 26675765
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation at 60 μg/d
Trial: 17901735
Drug: silver‐sulfadiazine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silver‐sulfadiazine cream
Trial: 12407041
Drug: 150 micro
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micro g desogestrel with testosterone pellets
Trial: 12407041
Drug: 300 micro
RxNorm normalized name: Voglibose 300 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micro g desogestrel with testosterone pellets
Trial: 12407041
Drug: 150 micro
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micro g and 300 micro g desogestrel with testosterone pellets
Trial: 12042267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral desogestrel with depot testosterone
Trial: 18098237
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ramipril
Trial: 17565489
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril
Trial: 2806622
Drug: Medium B
RxNorm normalized name: CVS Medium Briefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium B (2% UltroSer G)
Trial: 17668979
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg twice a day)
Trial: 2729930
Drug: Cefmetazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole (2 g intravenously)
Trial: 2729930
Drug: Cefmetazole with
RxNorm normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole with probenecid pretreatment (1 g orally)
Trial: 2729930
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g intravenously)
Trial: 31277120
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no eculizumab treatment)
Trial: 9578182
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (400 ml)
Trial: 15013031
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg p.o.)
Trial: 28153353
Drug: Nebulised magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised magnesium sulphate (1ml of 15% magnesium sulphate + 1.5ml isotonic saline) with nebulised salbutamol (0.15mg/kg/dose)
Trial: 28153353
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol (0.15mg/kg/dose) and 2.5ml isotonic saline (Placebo group)
Trial: 25279787
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose GQD (n=52)
Trial: 25279787
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GQD (n=50)
Trial: 11297577
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 18 months
Trial: 11297577
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 18 months
Trial: 9173675
Drug: Cerebrolysin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cerebrolysin infusion (20 ml in 500 ml Ringer) for 10 days
Trial: 9173675
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin B infusion 5 ml vitamin B complex in 500 ml Ringer) for 10 days
Trial: 31518023
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g CSO per ton
Trial: 31518023
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g CSO per ton
Trial: 31518023
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g CSO per ton)
Trial: 22390572
Drug: Heparin 100
RxNorm normalized name: heparin 100 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 100 U/mL
Trial: 18328639
Drug: Phentermine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine (60 mg)
Trial: 8686349
Drug: Olsalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (2 x 2 capsules of 250 mg)
Trial: 8686349
Drug: Mesalazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (3 x 2 tablets of 250 mg)
Trial: 1906745
Drug: OKT3 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OKT3 therapy for immunosuppression
Trial: 27096623
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg‐1)
Trial: 31852124
Drug: Drug +
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug + diet group
Trial: 16549954
Drug: Drug group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug group
Trial: 30027003
Drug: Cetirizine 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10‐mg once daily in the morning (QAM)
Trial: 30027003
Drug: Cetirizine 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10‐mg once daily at bedtime (QHS)
Trial: 30027003
Drug: Cetirizine 5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5‐mg twice daily
Trial: 30027003
Drug: Cetirizine 5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 5‐mg QAM
Trial: 30027003
Drug: Cetirizine 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10‐mg QHS
Trial: 30027003
Drug: Chlorpheniramine 8‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 8‐mg BID
Trial: 25081694
Drug: Beta glucan
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta glucan (two 10-mg capsules daily for 21 days)
Trial: 25081694
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules daily for 21 days)
Trial: 19434781
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies targeting immune-mediated disease mechanisms
Trial: 19434781
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies targeting distinct cell types and mechanisms
Trial: 14998579
Drug: Nimodipine tablets
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine tablets with pH 4.5 acetate buffer containing 0.3% SDS
Trial: 14998579
Drug: Two brands
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two brands of nimodipine tablets
Trial: 12865102
Drug: Albuterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (10 mg)
Trial: 22968823
Drug: Subconjunctival triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival triamcinolone injection
Trial: 30553026
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise intensity group (MG)
Trial: 26141208
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination of EGFR-TKI and chemotherapy
Trial: 26141208
Drug: No post-study
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No post-study treatments
Trial: 15478384
Drug: AeroChamber (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroChamber (200 microg of budesonide twice daily)
Trial: 11137829
Drug: Nisoldipine 40
RxNorm normalized name: nisoldipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 40 mg
Trial: 9537937
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (INR 2 to 3)
Trial: 9537937
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (INR 1.2 to 1.5) plus aspirin (325 mg/d)
Trial: 9537937
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (low-intensity warfarin plus aspirin)
Trial: 26647766
Drug: Self-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment group (STG)
Trial: 15811142
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times daily)
Trial: 1691134
Drug: High-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose Ara-C (3 g/m2 i.v. q 12 h days 1-4) and m-AMSA (120 mg/m2 i.v. day 5) for consolidation
Trial: 11835723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment)
Trial: 26511605
Drug: EPICENTER care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPICENTER care (multi-component treatment package including cognitive behavioral therapy, family psychoeducation, and metacognitive remediation)
Trial: 23227811
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets during the spring camp
Trial: 15522983
Drug: Pharmacist involvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist involvement in treatment
Trial: 12152676
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral vitamin K
Trial: 12017373
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg b.i.d.
Trial: 10433575
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.i.d.
Trial: 8131017
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine gel (10 ml intraurethrally)
Trial: 8131017
Drug: Plain lubricating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain lubricating gel (10 ml)
Trial: 88708
Drug: Midodrine (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (0.06 mg/kg/dose)
Trial: 22595386
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (4 g daily for 8 weeks)
Trial: 15214098
Drug: Reminiscence intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reminiscence intervention (weekly sessions)
Trial: 2634614
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms L-T3 (Thyrotardin)
Trial: 30475232
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous amisulpride
Trial: 27618796
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous amisulpride
Trial: 22278628
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8-12 mg once daily by forced titration)
Trial: 22278628
Drug: Azilsartan (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan (20-40 mg once daily by forced titration)
Trial: 18091641
Drug: 150 microg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg/m2 G‐CSF bis in die subcutaneously (from day 0 to day 4) in addition to standard care
Trial: 9528717
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution 200 mg/day for 14 days
Trial: 9528717
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution 200 mg/day for 7 days
Trial: 9528717
Drug: Fluconazole tablets
RxNorm normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole tablets 100 mg/day for 14 days
Trial: 7629001
Drug: Midaglizole (MID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midaglizole (MID) 300 mg/day for 1 week
Trial: 7629001
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (asthmatics not taking beta 2‐agonists)
Trial: 2930674
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 2 mg kg‐1 followed by an infusion of 2 mg kg‐1 h‐1
Trial: 25644122
Drug: Multiple intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravenous doses of 2.0 g cefozopran every 12 h for 4 days
Trial: 24219348
Drug: Renin angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin angiotensin system agents
Trial: 21255253
Drug: Episodic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic therapy with ≥25 IU kg(‐1) every 12‐24 h until complete clinical bleeding resolution
Trial: 17609623
Drug: Episodic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic therapy
Trial: 17396216
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (approximately 10 g/day over three months)
Trial: 12925827
Drug: Air-abrasion and
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-abrasion and Carisolv gel
Trial: 11037756
Drug: Water (control;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control; treatment A)
Trial: 9259871
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of nifedipine at 0.65 mg/h
Trial: 9259871
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of nifedipine at 1.25 mg/h
Trial: 27147900
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m²)
Trial: 29595562
Drug: Ramelteon (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (8 mg/d)
Trial: 20856164
Drug: JE-CV vaccine
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV vaccine (≥4 log10 plaque forming units) administered 1 month before or after hepatitis A control vaccine
Trial: 19035877
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg inhaled salbutamol via spacer device
Trial: 30242825
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg nebulized salbutamol
Trial: 7612060
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine bid
Trial: 16887123
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg extended-release niacin (n=20)
Trial: 15080372
Drug: Daily indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily indapamide (1 mg)
Trial: 15080372
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other day indapamide (1 mg)
Trial: 11841931
Drug: 5-FU/leucovorin (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/leucovorin (5-FU 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks)
Trial: 7926082
Drug: GnRH‐agonist (GnRH‐a)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐agonist (GnRH‐a) treatment
Trial: 28139830
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100 mg/day for 7 days)
Trial: 25888250
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS